Centralized HIV-1 immunogen approach is an important strategy to explore for preclinical testing to overcome HIV- diversity. For induction of neutralizing antibodies, centralized genes should capture the conserved Env regions that are important for virus infectivity. We have recently shown in initial proof of concept studies for use of consensus Envs for immunogen design, that year 1999 CON6 gp120 and gp140 Env proteins expressed wildtype Env neutralizing epitopes, and were able to induce antibodies that neutralized about 30% of wild-type HIV-1 primary isolates. The second proof of concept milestone needed for a firm rationale for the work proposed in Project 2 has also been achieved within the last year?that of demonstration of iterative improvement of consensus gene induction of neutralizing antibodies, with year 2001 anti-CON-S gp140CFI antibodies shown to neutralize the same spectrum of B isolates as CONG gp140, and, in addition, shown to neutralize a significant subset of non-B HIV-1 primary isolates. Project 2 will synergize with Projects 1, 3 and 4 and Cores B and C by exploring ways to further enhance the immunogenicity of centralized HIV-1 genes and proteins for their ability to induce more broadly reactive neutralizing anti-HIV-1 antibodies.
Specific Aim 1. To determine the immunogenicity of newer group M consensus and subtype consensus Envs compared to Year 2001 group M consensus Env, CON-S.
Specific Aim 2. To enhance the immunogenicity of Year 2001 CON-S Env for induction of neutralizing antibodies.
Specific Aim 3. To determine the antigenicity and immunogenicity of newly designed centralized Envs from Project 1 and Core B.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI061734-03
Application #
7404463
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2007-02-01
Budget End
2008-01-31
Support Year
3
Fiscal Year
2007
Total Cost
$307,534
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Pincus, Seth H; Song, Kejing; Maresh, Grace A et al. (2017) Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins. J Virol 91:
Pincus, Seth H; Song, Kejing; Maresh, Grace A et al. (2017) Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160. J Virol 91:
Go, Eden P; Liao, Hua-Xin; Alam, S Munir et al. (2013) Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins. J Proteome Res 12:1223-34
Liao, Hua-Xin; Chen, Xi; Munshaw, Supriya et al. (2011) Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med 208:2237-49
Kirchherr, Jennifer L; Hamilton, Jennifer; Lu, Xiaozhi et al. (2011) Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. Virology 409:163-74
Go, Eden P; Hewawasam, Geetha; Liao, Hua-Xin et al. (2011) Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J Virol 85:8270-84
Lu, Xiaozhi; Hora, Bhavna; Cai, Fangping et al. (2010) Generation of random mutant libraries with multiple primers in a single reaction. J Virol Methods 167:146-51
Tomaras, Georgia D; Haynes, Barton F (2010) Strategies for eliciting HIV-1 inhibitory antibodies. Curr Opin HIV AIDS 5:421-7
Barouch, Dan H; O'Brien, Kara L; Simmons, Nathaniel L et al. (2010) Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16:319-23
Salazar-Gonzalez, Jesus F; Salazar, Maria G; Keele, Brandon F et al. (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 206:1273-89

Showing the most recent 10 out of 27 publications